Compare Flux Power Holdings Inc (FLUX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs TG Therapeutics Inc — how do they compare? Flux Power Holdings Inc trades at $0.46 (market cap $9.97M), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 818.5× Flux Power Holdings Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and TG Therapeutics Inc for 16 Days on average.
| FLUX | TGTX | |
|---|---|---|
Market Cap | $9.97M | $8.16B |
Volume | 817,320 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $6.66 | $59.06 |
52-Week Low | $0.41 | $26.94 |
Typical Hold Time | 20 Days | 16 Days |
Enterprise Value | $18.18M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4612, down 5.92% today, with a bearish technical signal despite unanimous analyst buy ratings. The company reported declining revenue from $66M in 2025 to $42M in 2026 while maintaining a net loss of -$7M. Recent news highlights a rejected acquisition offer from Solidion Technology, creating uncertainty around strategic direction.
The stock faces fundamental challenges with negative profitability metrics but maintains a low P/S ratio of 0.22. Investment opportunity exists if operational improvements materialize, while risks include persistent losses and acquisition-related volatility. Analyst consensus remains optimistic with 6 buy ratings despite recent earnings misses.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
